BioMark is an oncology-focused company with advanced near-to- market diagnostic technologies designed to improve patient outcomes. We have developed and own multiple intellectual properties (IPs) in detection and quantitation of metabolites.
We hand-picked a proven, global enterprise team of scientists, engineers and medical professionals to help commercialize our innovative technology and to increase prediction and accuracy in the diagnosis of cancers by following and incorporating the highest regulatory ,clinical and scientific standards..
Our cross pollinated, balanced and committed team was established in 2007. Our mission is to develop and commercialize innovative technologies to increase prediction and accuracy in diagnosis of cancers.
To empower people, medical institutions and nations to gain universal access to effective cancer diagnostic tools.
In essence, we accelerate and facilitate effective cancer management solutions to improve patient outcome.
Because of the critical role that biomarkers play at all stages of disease, it is important that they undergo rigorous evaluation, including analytical validation, clinical validation, and assessment of clinical utility, prior to incorporation into routine clinical care. This is an important dimension of BioMark’s daily operational activity.
Dr. Daniel Sitar – Principal Scientific Advisor / Professor Emeritus, University of Manitoba
Dr. David Wishart – Professor, Depts. of Computer Science and Biological Sciences, University of Alberta
Dr. Myron L. Weifeldt – M.D., University Distinguished Service Professor, Professor of Medicine, The Johns Hopkins Hospital
Dr. Ian C.P. Smith – Officer of the Order of Canada, PhD, DSc, FRSC
Dr. Andrew Maksymiuk – Oncologist; Cancer Care Manitoba
Dr. James Bond – Chief of Surrey Hospital Thoracic Surgery Team, Fraser Health Authority and Surrey Memorial Hospital
Dr. John Yoo – Clinical Oncologist – Co-Chair CancerCare Ontario Head and Neck; Professor Dept. of Oncology Schulich School of Medicine & Dentistry, Western Ontario
Dr. David Chen – Professor, Dept. of Chemistry, University of British Columbia
Dr. Safieddin Safavi-Naeini – NSERC/BlackBerry Industrial Research Chair at University of Waterloo
Dr. Malcolm Kennard – PhD, Drug and medical device development
Dr. Horacio Bach – PhD, Antibody Engineering UBC
Rashid Ahmed, MBA – Founder, Chief Executive Officer
Dr. Thomas Malcolm, Ph.D – Chief Scientific Officer
Dr. Bram Ramjiawan, Ph.D – Clinical Trial and Regulatory Expertise
Brian Cheng, MSc– Chief Technical Officer
Dr. Kenneth Kohn, Ph.D – Patent Attorney
Gina Huang, MBA – CFO and Project Director
Manning Elliott Accountants & Business Advisors
Miller Thomas LLP.